Drug Trial Radar · NCT05437263
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
241
Actual
Start
Oct 31, 2022
Primary completion
Jul 17, 2025
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- Priovant Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib.
Conditions
- Dermatomyositis
Interventions
BrepocitinibDrug
Oral Brepocitinib
PlaceboDrug
Oral Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Improvement Score (TIS) at Week 52Time frame: 52 weeks
Locations
109 sites in 22 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Phoenix, Arizona
Clinical Trial Site
Scottsdale, Arizona
Clinical Trial Site
Scottsdale, Arizona
Clinical Trial Site
Irvine, California
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
San Francisco, California
Clinical Trial Site
Aurora, Colorado
Clinical Trial Site
Denver, Colorado
Clinical Trial Site
Boynton Beach, Florida
Clinical Trial Site
Gainesville, Florida
Clinical Trial Site
Jacksonville, Florida
Clinical Trial Site
Plantation, Florida
Clinical Trial Site
Tampa, Florida
Clinical Trial Site
Atlanta, Georgia
Clinical Trial Site
Augusta, Georgia
Clinical Trial Site
Marietta, Georgia
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Iowa City, Iowa
Clinical Trial Site
Kansas City, Kansas
Clinical Trial Site
New Orleans, Louisiana
Clinical Trial Site
New Orleans, Louisiana
Clinical Trial Site
Baltimore, Maryland
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Ann Arbor, Michigan
Clinical Trial Site
Minneapolis, Minnesota
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
Manhasset, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Cincinnati, Ohio
Clinical Trial Site
Cleveland, Ohio
Clinical Trial Site
Oklahoma City, Oklahoma
Clinical Trial Site
Portland, Oregon
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Pittsburgh, Pennsylvania
Clinical Trial Site
Jackson, Tennessee
Clinical Trial Site
Austin, Texas
Clinical Trial Site
Houston, Texas
Clinical Trial Site
Irving, Texas
Clinical Trial Site
Mendoza, Argentina
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.